Former Allergan program posts positive topline PhIII results in farsightedness in an R&D win post-AbbVie merger

The battered pipeline AbbVie $ABBV acquired in its $63 billion buyout of Allergan picked up a rare win Wednesday morning.

Allergan announced that a pair of Phase III studies for an experimental ophthalmic solution in presbyopia, or farsightedness, met their primary endpoint in vision tests associated with the condition. The data puts the program on track for a NDA sometime in the first half of next year.